Navigation Links
LA BioMed's Dr. John Tsuang examines effects of Ibudilast and metamphetamines
Date:4/25/2012

LOS ANGELES (April 25, 2012) John W. Tsuang, M.D., principal investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), in conjunction with Steven J. Shoptaw, Ph.D., from the UCLA Department of Family Medicine, is spearheading a Phase I clinical safety trial that for the first time examines the effects of Ibudilast when administered with metamphetamine (MA), an addictive stimulant that is closely related to amphetamine. Ibudilast is a non-selective phosphodiesterase inhibitor known as a modulator of glial activation in the central nervous system; the role of these glial cells is to regulate the repair of neurons after an injury, such as the neurocognitive deficits caused by long-term MA addiction. The study is being funded by the National Institutes of Health National Institute on Drug Abuse (NIDA).

More commonly known as "speed," "meth" or "ice," MA is long lasting and toxic to dopamine nerve terminals in the central nervous system (NIDA). According to the Substance Abuse and Mental Health Services Administration (SAMHSA), a 2009 survey revealed that 1.2 million Americans ages 12 and older had abused MA at least once prior to the year they were surveyed. According to the SAMHSA, MA dependence causes devastating personal and public health consequences, particularly in the Western and Midwestern United States.

"Currently, there are no approved medications to help treat MA dependence," said Dr. Tsuang. "Through this study, we are working to determine the effects of Ibudilast - combined with relevant doses of MA - on heart rate and blood pressure, and whether or not Ibudilast alters the way in which the body absorbs, distributes, and metabolizes MA. The development of one or more medications to reduce MA abuse, when implemented with evidence-based behavioral and counseling interventions, would have obvious public health significance."

Dr. Tsuang and his colleagues are utilizing a randomized double-blind, placebo-controlled within-subject crossover design to determine the safety and tolerability and subjective and reinforcing effects of MA in 12 participants who are not seeking treatment for MA dependence. The participants will be treated with oral Ibudilast (20mg BID and 50mg BID) and placebo.

Recent research suggests that glial cells may be important in modulating the rewarding properties of drugs that are abused, including MA. Research also suggests that MA-induced glial activation may help reduce the damage done to the central nervous system and associated cognitive dysfunction via glial cell secretion of pro-inflammatory cytokines, which are proteins that interact with cells of the immune system in order to regulate the body's response to disease and infection.

Dr. Tsuang is hoping that following the initial safety trial, physicians will be able to utilize Ibudilast in treating patients with MA dependence to help them improve memory and reduce the damage done to their central nervous system due to MA abuse.


'/>"/>

Contact: Diana Soltesz
diana@dsmmedia.com
818-592-6747
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. Ming T. Tsuang recognized with NARSAD outstanding achievement award for schizophrenia research
2. New Research Examines Impact of Health Care Reform on Regional Health Plans
3. New national study examines weight training-related injuries
4. Cedars-Sinai study examines regional use of minimally invasive repair of aneurysms
5. AERA journal examines research issues
6. CWRU study examines effectiveness of telemonitoring vital signs
7. AP-CNBC Poll Examines "Marijuana & Money"
8. DSM Personalized Nutrition Webinar Examines Ways to Build Engagement in Wellness Programs
9. Study examines global availability of treatment involving transplantation of blood stem cells
10. Wednesday, May 26: Forum Examines State of Literacy In Connecticut
11. UAB study examines hearing loss, Viagra use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Jericho Project has named LaToya Williams-Belfort to ... be responsible for fundraising and communications for the nationally-acclaimed nonprofit, working closely with CEO ... working to end homelessness at its roots. , “LaToya Williams-Belfort is joining Jericho ...
(Date:5/24/2016)... ... May 24, 2016 , ... How to Write Error ... NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major cause ... error will ever be totally eliminated, many human performance problems can be prevented. , ...
(Date:5/24/2016)... ... May 24, 2016 , ... Loma Linda University Health (LLUH) has ... and expanded Children’s Hospital. Over 3,000 people looked on as the shovels hit the ... event photo slidehsow. , During the program, Richard H. Hart, MD, DrPH, president, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Eggsurance, the first ... relaunch of its community and education hub for women considering fertility preservation, as ... create a safe and welcoming place for women to find cycle buddies, get ...
(Date:5/24/2016)... ... May 24, 2016 , ... Tuesday, May 24, Women's Excellence ... practice enhanced with Young Living Essential Oils, taught by Patti Dolan, RYT, a ... Orion location. Yoga Flow is 6:30pm - 7:15pm followed by a small intro to ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... --Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today the start ... hands-on learning experience is a 12-week summer program, May ... and Internship programs bring participants to ... are provided optional housing free of charge through Diplomat ... Riverfront Residence Hall to foster communication and collaboration among ...
(Date:5/23/2016)... , May 23, 2016 ... Market Size, Share, Development, Growth and Demand Forecast ... Single and Other), by Application (Drug Discovery and ... End Users (Pharmaceuticals, Life Science and Biotechnology, Academic ... P&S Market Research, the global mass spectrometry ...
(Date:5/23/2016)... 2016 The World Health Organization (WHO) expanded the ... include adolescents aged 13 years, and above. Effective immediately, the ... adult and adolescent males in the 14 priority countries in ... the first male circumcision device to receive WHO Prequalification on ... Horowitz said: " The expanded use of ...
Breaking Medicine Technology: